PT - JOURNAL ARTICLE AU - Taylor, JE AU - Oka, T AU - Murakami, M AU - Motegi, T AU - Yamada, T AU - Kawashima, T AU - Kobayashi, Y AU - Yoshihara, Y AU - Miyata, J AU - Murai, T AU - Kawato, M AU - Cortese, A TI - Paving the way for precision treatment of psychiatric symptoms with functional connectivity neurofeedback AID - 10.1101/2024.04.03.24304187 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.03.24304187 4099 - http://medrxiv.org/content/early/2024/04/03/2024.04.03.24304187.short 4100 - http://medrxiv.org/content/early/2024/04/03/2024.04.03.24304187.full AB - Despite the prevalence of Major depressive disorder (MDD), a large proportion of patients do not respond well to its existing treatments. Patients with MDD have heterogeneous transdiagnostic subsets of symptoms with differing underlying neural aberrations. Therefore, better treatment response might be achieved using more customizable treatments. Showing promise for this, brain-machine interfaces (BMIs) can be used to directly target patient-specific underlying neural aberrations. As a major step in this direction, here we reproduce and extend, with a larger sample, our previous findings that a BMI technique called Functional Connectivity Neurofeedback (FCNef) can normalize neural aberrations related to specific MDD symptoms. For the first time, we show that normalization of the target neural activity (here, connectivity between the dorsolateral prefrontal cortex and the precuneus) corresponds meaningfully more to reductions in corresponding than non-corresponding symptoms (here, significantly more to reductions in rumination than anxiety symptoms). Furthermore, we showed for the first time that this depended on the specific parameters that FCNef was run with. Specifically, normalization of the targeted neural activity and a corresponding reduction in related symptoms was greater with more external reward and with consecutive (compared to non-consecutive) days of training, but did not differ depending on whether participants were given shorter or longer time-windows to manipulate their neural activity. Overall, these findings demonstrate the promise of FCNef for precision medicine and highlight the importance of BMI parameter testing for enhancing the feasibility of actual clinical trials. Hereby, we inch closer to a future where signals from our own brains are used to guide our own individual medical interventions.Competing Interest StatementTY and MK are inventors of patents related to the functional connectivity neurofeedback method. The original assignee of the patents is ATR, with which the authors are affiliated. We have no other conflicts of interest.Clinical TrialUMIN000015249 jRCTs052180169Funding StatementThis work was supported by the contract research Brain/MINDS Beyond (Grant Number JP18dm0307008, JP21dm0307102h0003), from the Japan Agency for Medical Research and Development (AMED). It was also supported by Application of DecNef for Development of Diagnostic and Cure System for Mental Disorders and Construction of Clinical Application Bases under Development of BMI Technologies for Clinical Application of the Strategic Research Program for Brain Sciences, (Grant Number JP17dm0107044; AMED), and Innovative Science and Technology Initiative for Security, ATLA, Japan (Grant Number JPJ004596).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics Committee of the Review Board of Advanced Telecommunications Research Institute International, Japan and the Kyoto University Certified Review Board gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors